The magnitude of the antigen-specific T cell response is separated from the severity of spinal cord histopathology in remitting-relapsing experimental autoimmune encephalomyelitis

GLIA

Volumn 60, Issue 5, 2012, Pages 794-805

  Batoulis, Helena ^a   Uhl, Martin ^a   Addicks, Klaus ^a   Lehmann, Paul V ^b,c   Kuerten, Stefanie ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Cellular Technology Limited   (United States)

Author keywords

EAE; IL 1 ; Macrophages microglia; MS; Relapse; TH1; TH17

Indexed keywords

INTERLEUKIN 1BETA; PROTEOLIPID PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DEMYELINATION; DISEASE SEVERITY; FEMALE; HELPER CELL; HISTOPATHOLOGY; IMMUNE RESPONSE; MACROPHAGE; MICROGLIA; MOUSE; MULTIPLE SCLEROSIS; NERVE FIBER; NONHUMAN; PRIORITY JOURNAL; RELAPSE; SPINAL CORD;

ANIMALS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; EPITOPES, T-LYMPHOCYTE; FEMALE; MICE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; SEVERITY OF ILLNESS INDEX; SPINAL CORD;

EID: 84858081649     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.22309     Document Type: Article

References (33)

1. Almolda B, Gonzalez B, Castellano B. 2011. Antigen presentation in EAE: Role of microglia, macrophages and dendritic cells. Front Biosci 16: 1157-1171.
2. Bannerman PG, Hahn A, Ramirez S, Morley M, Bönnemann C, Yu S, Zhang GX, Rostami A, Pleasure D. 2005. Motor neuron pathology in experimental autoimmune encephalomyelitis: Studies in THYI-YFP transgenic mice. Brain 128: 1877-1886.
3. H1 paradigm. Ann Anat 192: 179-193.
4. Becher B, Durell BG, Miga AV, Hickey WF, Noelle RJ. 2001. The clinical course of experimental autoimmune encephalomyelitis and inflammation is controlled by the expression of CD40 within the central nervous system. J Exp Med 193: 967-974.
5. Begolka WS, Vanderlugt CL, Rahbe SM, Miller SD. 1998. Differential expression of inflammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis. J Immunol 161: 4437-4446.
6. Benveniste EN. 1997. Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J Mol Med (Berl) 75: 165-173.
7. Chastain EM, Duncan DS, Rodgers JM, Miller SD. 2011. The role of antigen presenting cells in multiple sclerosis. Biochim Biophys Acta 1812: 265-274.
8. de Haas AD, Boddeke HW, Biber K. 2008. Region-specific expression of immunoregulatory proteins on microglia in the healthy CNS. Glia 56: 888-894.
9. Graber MB. 2010. Changing face of microglia. Science 330: 783-788.
10. Hanisch UK, Kettenmann H. 2007. Microglia: Active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 10: 1387-1394.
11. Hendriks JJ, Teunissen CE, de Vries HE, Dijkstra CD. 2005. Macrophages and neurodegeneration. Brain Res Brain Res Rev 48: 185-195.
12. Hofstetter HH, Toyka KV, Tary-Lehmann M, Lehmann PV. 2007. Kinetics and organ distribution of IL-17-producing CD4 cells in proteolipid protein 139-151 peptide-induced experimental autoimmune encephalomyelitis of SJL mice. J Immunol 178: 1372-1378.
13. Kuerten S, Rottlaender A, Rodi M, Velasco VBJr, Schroeter M, Kaiser C, Addicks K, Tary-Lehmann M, Lehmann PV. 2010. The clinical course of EAE is reflected by the dynamics of the neuroantigen-specific T cell compartment in the blood. Clin Immunol 137: 422-432.
14. Laman JD, Visser L, Maassen CB, de Groot CJ, de Jong LA, 't Hart BA, van Meurs M, Schellekens MM. 2001. Novel monoclonal antibodies against proteolipid protein peptide 139-151 demonstrate demyelination and myelin uptake by macrophages in MS and marmoset EAE lesions. J Neuroimmunol 119: 124-130.
15. Lassmann H, Ransohoff RM. 2004. The CD4-Th1 model for multiple sclerosis: A crucial re-appraisal. Trends Immunol 25: 132-137.
16. Lyons JA, San M, Happ MP, Cross AH. 1999. B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide. Eur J Immunol 29: 3432-3439.
17. Marta CB, Oliver AR, Sweet RA, Pfeiffer SE, Ruddle NH. 2005. Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology. Proc Natl Acad Sci USA 102: 13992-13997.
18. Mathey EK, Derfuss T, Storch MK, Williams KR, Hales K, Woolley DR, Al-Hayani A, Davies SN, Rasband MN, Olsson T, Moldenhauer A, Velhin S, Hohlfeld R, Meinl E, Linington C. 2007. Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med 204: 2363-2372.
19. McRae BL, Kennedy MK, Tan LJ, Dal Canto MC, Picha KS, Miller SD. 1992. Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein. J Neuroimmunol 38: 229-240.
20. McRae BL, Vanderlugt CL, Dal Canto MC, Miller SD. 1995. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med 182: 75-85.
21. Miller SD, Vanderlugt CL, Lenschow DJ, Pope JG, Karandikar NJ, Dal Canto MC, Bluestone JA. 1995. Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. Immunity 3: 739-745.
22. Olah M, Biber K, Binet J, Boddeke HW. 2001. Microglia phenotype diversity. CNS Neurol Disord Drug Targets 10: 108-118.
23. Oliver AR, Lyon GM, Ruddle NH. 2003. Rat and human myelin oligodendrocyte glycoproteins induce experimental autoimmune encephalomyelitis by different mechanisms in C57BL/6 mice. J Immunol 171: 462-468.
24. Perry VH, Nicoll JA, Holmes C. 2010. Microglia in neurodegenerative disease. Nat Rev Neurol 6: 193-201.
25. Steinman L. 2007. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 13: 139-145.
26. Stromnes IM, Goverman JM. 2006. Passive induction of experimental allergic encephalomyelitis. Nat Protoc 1: 1952-1960.
27. Takahashi JL, Giuliana F, Power C, Imai Y, Wee Yong V. 2003. Interleukin-1β promotes oligodendrocyte death through glutamate excitotoxicity. Ann Neurol 53: 588-595.
28. Targoni OS, Baus J, Hofstetter HH, Hesse MD, Karulin AY, Boehm BO, Forsthuber TG, Lehmann PV. 2001. Frequencies of neuroantigen-specific T cells in the central nervous system versus the immune periphery during the course of experimental allergic encephalomyelitis. J Immunol 166: 4757-4764.
29. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. 1998. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338: 278-285.
30. Trapp BD, Ransohoff R, Rudick R. 1999. Axonal pathology in multiple sclerosis: Relationship to neurologic disability. Curr Opin Neurol 12: 295-302.
31. Vanderlugt CL, Neville KL, Nikcevich KM, Eagar TN, Bluestone JA, Miller SD. 2000. Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis. J Immunol 164: 670-678.
32. von Büdingen HC, Hauser SL, Ouallet JC, Tanuma N, Menge T, Genain CP. 2004. Frontline: Epitope recognition on the myelin/oligodendrocyte glycoprotein differentially influences disease phenotype and antibody effector functions in autoimmune demyelination. Eur J Immunol 34: 2072-2083.
33. Zehntner SP, Brisebois M, Tran E, Owens T, Fournier S. 2003. Constitutive expression of a costimulatory ligand on antigen-presenting cells in the nervous system drives demyelinating disease. FASEB J 17: 1910-1912.